Form 4: Aeon Biopharma CEO Granted Stock Options

Robert E. Bancroft, President & CEO of Aeon Biopharma, Inc., was granted stock options for 59,034 shares on April 29, 2025.

Summary

• Robert E. Bancroft, the President & CEO of Aeon Biopharma, Inc. [AEON], received stock options.
• The transaction occurred on April 29, 2025.
• Bancroft was granted options for 59,034 shares of Class A Common Stock at an exercise price of $0.41 per share.
• The options vest 25% annually, starting April 29, 2025, and will be fully vested by the fourth anniversary.
• Following the transaction, Bancroft directly owns options for 59,034 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule of 25% per year is a typical arrangement to ensure long-term commitment.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to increase company value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, AEON Biopharma, Robert E. Bancroft, executive compensation, insider transaction